ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Chandra Bhagat Pharma Limited has intimated a board meeting on 13 November 2026 to consider unaudited standalone half-yearly financial results for the period ended September 2026. The trading window closes from 1 October to 16 November 2026.
Chandra Bhagat Pharma allotted 50 lakh convertible warrants worth ₹21.90 Crore to seven promoter group members. Allotment was completed on 22 October 2026.
Chandra Bhagat Pharma allotted 66 lakh convertible warrants at Rs.44 each, raising Rs.7.26 Crore from 9 allottees. Warrants are convertible 1:1 into equity shares within 18 months.
Chandra Bhagat Pharma Ltd filed a certificate for non-applicability of corporate governance requirements for the September 2026 quarter. This exemption applies to SME-listed entities.
Chandra Bhagat Pharma received BSE in-principle approval for a preferential issue of 66,00,000 warrants at Rs. 44 each. Total issue value is approximately Rs. 2.90 Crore.
Ms. Rajani Dawani has resigned from her position as Company Secretary and Compliance Officer of Chandra Bhagat Pharma Limited, effective September 30, 2026.
Chandra Bhagat Pharma Limited conducted its 23rd Annual General Meeting on September 1, 2026, covering annual accounts, director reappointment, capital increase, and warrant issuance.
Chandra Bhagat Pharma Limited issued a corrigendum to its AGM notice regarding a proposed preferential issue. The update provides a web link to the required compliance certificate.
Chandra Bhagat Pharma Limited has issued a notice for its Annual General Meeting scheduled for September 1, 2026, to discuss financial and corporate resolutions.
Chandra Bhagat Pharma Ltd has submitted its Annual Report for the financial year 2025-26 and notice for the 23rd Annual General Meeting.
Chandra Bhagat Pharma Limited approved a preferential issue of 66 lakh convertible warrants worth Rs 29.04 crore and increased its authorized share capital.
Chandra Bhagat Pharma scheduled a board meeting for August 5, 2026. The agenda includes considering a fundraise via preferential allotment and increasing authorized share capital.
Chandra Bhagat Pharma Ltd reported revenue from operations of ₹90.7 Cr (+316.1% YoY) and net profit of ₹2.6 Cr (+1200.0% YoY) for H2 FY26.
Chandra Bhagat Pharma reported annual revenue of ₹116.27 Crore for FY2026. The Board approved audited results with an unmodified audit opinion, showing steady growth.
Chandra Bhagat Pharma scheduled a board meeting on May 25, 2026, to consider audited financial statements. The meeting will review results for the fiscal year-end.
Chandra Bhagat Pharma Limited submitted a certificate confirming the non-applicability of Corporate Governance report requirements for the quarter ended March 31, 2026. As an SME Exchange listed entity, it falls under the SEBI Regulation 15(2) exemption criteria.